Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytek Biosciences (CTKB) Cash & Equivalents (2020 - 2026)

Cytek Biosciences filings provide 6 years of Cash & Equivalents readings, the most recent being $90.9 million for Q4 2025.

  • On a quarterly basis, Cash & Equivalents fell 7.97% to $90.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was $90.9 million, a 7.97% decrease, with the full-year FY2025 number at $90.9 million, down 7.97% from a year prior.
  • Cash & Equivalents hit $90.9 million in Q4 2025 for Cytek Biosciences, down from $93.3 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $364.6 million in Q4 2021 to a low of $75.5 million in Q2 2025.
  • Median Cash & Equivalents over the past 5 years was $163.6 million (2023), compared with a mean of $197.4 million.
  • Biggest five-year swings in Cash & Equivalents: skyrocketed 132.67% in 2022 and later crashed 62.42% in 2023.
  • Cytek Biosciences' Cash & Equivalents stood at $364.6 million in 2021, then fell by 18.65% to $296.6 million in 2022, then plummeted by 43.59% to $167.3 million in 2023, then tumbled by 40.99% to $98.7 million in 2024, then decreased by 7.97% to $90.9 million in 2025.
  • The last three reported values for Cash & Equivalents were $90.9 million (Q4 2025), $93.3 million (Q3 2025), and $75.5 million (Q2 2025) per Business Quant data.